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ORIGINAL ARTICLE
Vitamin D regulates the tight-junction protein expression in active ulcerative
colitis
Maria Stioa, Luigina Reticob, Vito Anneseb and Andrea Giovanni Bonanomib
aDepartment of Biomedical, Experimental and Clinical Sciences, ‘‘Mario Serio’’ University of Florence, Florence, Italy; bGastroenterology Unit,
Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
ABSTRACT
Objective: Epithelial barrier function is primarily regulated by the tight-junction proteins. Ulcerative col-
itis (UC) is characterized by Th2 immune response with inflammation and epithelial barrier dysfunction,
including an elevation of claudin-2 protein function. Recent studies support an important role of vitamin
D in the pathogenesis as well as potential therapy of IBD. Vitamin D deficiency is in fact common in
patients with IBD. The aim of the study was to determine whether vitamin D could affect IL-13 and IL-6
levels, and regulate the activity of tight-junction proteins. Claudin-1, -2, -4, and -7 in the inflamed and
non-inflamed colonic mucosa of UC patients.
Material and methods: Biopsies from inflamed and non-inflamed tract of colon and rectum from the
same active UC patients were cultured with1,25(OH)2D3. IL-13, IL-6 and the tight-junction proteins level
were determined.
Results: Claudin-1 and claudin-2 proteins were up-regulated in active UC. The treatment with
1,25(OH)2D3 decreases the claudin-1 and claudin-2 protein levels in both inflamed and non-inflamed
tract. Claudin-4 and claudin-7 proteins were down-regulated and their levels increase after incubation
with the 1,25(OH)2D3. When the biopsies were incubated with 1,25(OH)2D3, a decrease in IL-13 and IL-6
levels was registered.
Conclusions: Our results, indicating the inhibition of cytokine levels and the regulation of claudin-2,
claudin-4, and claudin-7 by 1,25(OH)2D3, suggest that vitamin D may represent a potential therapeutic
agent for the treatment of active UC.
ARTICLE HISTORY
Received 8 March 2016
Revised 26 April 2016
Accepted 28 April 2016
Published online 19 May 2016
KEYWORDS
Tight-junctions proteins;
ulcerative colitis; vitamin D
Introduction
Inflammatory bowel diseases (IBD), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are chronic disorders
involving mainly the gastrointestinal tract, although extra
intestinal manifestations can be present in up to 40% of
patients.[1] While the pathogenesis of IBD remains unclear,
it is generally hypothesized to be a multifactorial condition
where a combination of luminal, environmental, and gen-
etic factors triggers an inappropriate mucosal immune
response.
As a consequence, an inappropriate and continuing inflam-
matory response to commensal microbes results in the spon-
taneous release of pro-inflammatory cytokines, which
challenge the mucosal homeostasis.[2] These changes are in
part genetically determined and might lead to a dysfunction
of the barrier integrity and changes in the regulation of adap-
tive immune responses in both UC and CD.[3]
Inflammation in IBD is regulated by an increased secretion
of a variety of pro-inflammatory mediators.[4] The uniform
mucosal inflammation of the colon found in patients with UC
is suggested to be associated with a Th2 immune response
mediated by IL-4, IL-5, and IL-13 that results in an increase in
levels of IL-13.[4]
In IBD, epithelial barrier function is impaired contributing
to diarrhea by a leak flux mechanism and perpetuating
inflammation by an increased luminal antigen uptake.
This barrier of the intestinal epithelial is maintained by
intracellular junctional complexes, such as tight-junctions (TJ),
adherens junctions, and desmosomes. TJ are located at the
most apical part of the cell’s lateral membranes. Claudin (Cl)
proteins comprise a family of TJ proteins that differentially
regulate paracellular permeability through their homophilic
and heterophilic interactions with other adjacent claudins.[5]
In response to pathogens and during inflammation, increased
claudin internalization can result in a deleterious increase in
paracellular permeability. Host factors and cytokines can also
influence tight-junction turnover and claudin expression, pre-
sumably in part to accommodate neutrophil migration across
epithelial barriers.[6] The pathophysiological mechanisms
leading to this barrier defect in IBD are still unclear. In UC,
epithelial leaks appear early due to micro-erosions resulting
from the up-regulation of epithelial apoptosis and from an
increase in Cl-2.[7]
In contrast, Cl-4 and Cl-7 are down-regulated in UC.[5]
Down-regulation of CL-4 and CL-7, and up-regulation of CL-2
might lead to altered TJ structure and might be related to
the impaired epithelial function in active UC.[5]
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It has been reported that IL-13 in UC stimulates apoptosis
and up-regulates claudin-2 expression,[7] while it does not
affect claudin-1 and claudin-4.[8]
Vitamin D is essential for bone mineralization and calcium
homeostasis. However, several studies have yielded new
insights into other important roles of vitamin D in many
physiological processes. In particular, vitamin D appears to
play an important role in immune regulation.[9,10]
Importantly, recent literature supports a key role of vitamin D
in the pathogenesis as well as potential therapy of IBD.[11] A
deficiency of vitamin D could be a consequence of IBD itself
with reduced physical activity, sunlight exposure, malnutrition,
inadequate dietary intake of vitamin D, or lower bioavailabil-
ity, all contributing to deficiency.[12–14] However, the fact
that vitamin D deficiency is common even in newly diag-
nosed IBD patients suggests that low vitamin D itself can lead
to an increased risk of IBD.[15]
We investigated the expression of claudins (Cl-1, -2, -4, -7)
that show alterations in distribution or expression in IBD, and
the effects of the active hormonal form of vitamin D,
1,25(OH)2D3, on these proteins. Moreover, the aims of this
study was to investigate whether 1,25(OH)2D3 could regulate
IL-13 and IL-6 production. IL-6 is a pro-inflammatory cytokine
that in IBD is associated with the initiation and progression of
UC and CD.[16] IL-13 is an effector cytokine in intestinal path-
ology of UC, which can induce erosions and ulcer-type lesions
by epithelial restitution arrest. Neutralization of IL-13 could
decrease Cl-2 protein expression and interrupt tissue destruc-
tion by activated immune cells.
Methods
Subjects
Informed consent was obtained from all subjects.
Biopsies were taken at routine diagnostic colonoscopies
from 10 subjects with active UC, four men and six women
with a mean age of 39.25 yr (range 25-55) and 54.7 yr (range
38-63), respectively. The diagnosis of UC was established on
the basis of clinical symptoms and on endoscopic, histo-
logical, radiological demonstration, and pathologic criteria, as
described by Lennard-Jones.[17] Biopsy samples were taken
from endoscopic inflamed (I) and non-inflamed (NI) area of
the colon from the same subject. Subject characteristics are
reported in Table 1.
The histological assessments at biopsy sites confirmed the
severity of inflammation.[18]
Materials
Biopsies were obtained by Single use biopsy Forceps Jumbo
Ra dial Jaw 4, Boston Scientific, Boston, MA. The size of each
single biopsy was at least 4mm. RPMI 1640 medium Hepes
modification, PBS, heat inactivated FBS, L-glutamine and anti-
biotics were obtained from Sigma (St. Louis, MO). 1 10 2 M
1,25(OH)2D3 in isopropanol was a generous gift from Bayer
Shering Pharma Aktiengesellschaft (Berlin, Germany). Stock
solutions were stored at 20 C, protected from light and
freshly diluted in culture medium before each experiment.
Claudin-1, -2, -4, -7, -and b-actin antibodies, and horseradish
peroxidase-conjugated secondary antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). IL-13 and IL-
6 Elisa kit were obtained from Vinci-Biochem (Florence, Italy).
All other chemicals were of the highest grade available from
E. Merck (Darmstadt, Germany), Sigma (Saint Louis, MO), and
Bio-Rad Laboratories (Milano, Italy).
Culture conditions
Four biopsies were obtained from each subject, two from the
inflamed tract (I) and two from non-inflamed tract (NI). When
possible, the biopsies were immediately placed into culture
media otherwise stored at 80 C until their utilization.
Table 1. Clinical characteristics of the subjects.
Subjects (Initials) Sex Age Disease duration UC extent Site of I biopsy Site of NI biopsy Mayo Score On-going treatment
C A F 61 6 RS Sigma Descending colon 2 5-ASA
M R F 38 12 EC Sigma Ascending colon 5-ASA
D G F 63 31 EC Sigma Caecum 2 Steroids5-ASA
FM F 53 22 LS Sigma Transverse colon 2 Steroids5-ASA
C P F 59 18 EC Descending colon Caecum 3 Steroids5-ASA
B L F 54 3 EC Sigma Caecum 3 Steroids5-ASA
A C M 55 8 LS Sigma Transverse colon 3 5-ASA
G R M 25 3 EC Sigma Ascending colon 2 5-ASA
R S M 26 15 EC Descending colon Caecum 2 5-ASA
Z R M 51 4 RS Sigma Transverse colon 2 5-ASA
I: Inflamed; NI: non-inflamed.
UC: ulcerative colitis; RS: rectum and sigmoid colon; LS: left side colitis; EC: extensive colitis.
Table 2. Levels of claudins, IL-13 and IL-6 in intestinal biopsies.
Intestinal tract CL-1 CL-2 CL-4 CL-7 IL-13 pg/mg protein IL-6 pg/mg protein
NI 0.41 ± 0.19 0.26 ± 0.07 0.34 ± 0.13 0.91 ± 0.16 34.42 ± 3.2 104.8 ± 11.3
I 1.11 ± 0.2* 0.75 ± 0.16* 0.18 ± 0.01* 0.26 ± 0.04* 85.1 ± 8.1* 289.2 ± 29.4*
Claudins were determined by Western blot analysis in total lysate. IL-13 and IL-6 were assayed with ELISA in culture medium from intestinal
biopsies.
The values of claudins represent the ratio between the densitometric analysis of the claudin band and the respective b-actin band. Each
value represents the mean ± S.D. of 10 separate experiments.
CL: Claudin; NI: non-inflamed (tract); I: inflamed (tract).
*p< 0.05 (in comparison with the respective NI).
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Biopsies were cultured for 24 h in 250 ll of RPMI 1640 supple-
mented with 25mM Hepes, 10% (v/v) heat inactivated FBS,
60mg/l (100 U/ml) penicillin, 100mg/l streptomycin, 0.29 g/l L-
glutamine, and incubated in the presence of vehicle alone or
100 nM 1,25(OH)2D3. The vehicle was represented by the cul-
ture medium with isopropanol at the same concentration
used in the experiments with 1,25(OH)2D3. We investigated
40 cultures, 20 cultures (10 related to NI tract and 10 related
to I tract) not incubated with 1,25(OH)2D3, 20 incubated with
1,25(OH)2D3 (10 related to NI tract and 10 related to I tract).
The cultures were maintained at 37 C in humidified atmos-
phere containing 5% CO2. At the end of the incubation, the
medium was collected and used for the determination of the
levels of interleukins. Biopsies were homogenized in lysis buf-
fer (10mM Hepes, 150mM NaCl, 1mM EDTA 0.6% NP-40,
0.5mM PMSF, 1 lg/ml leupeptin, 1 lg/ml aprotinin, and
0.5 lg/ml pepstatin). The homogenate was centrifuged at
10,000g for 15min at 4 C, and the supernatant was used for
protein determination and Western Blot Analysis.
Protein determination
Protein concentration was determined by the Bradford
method [19], using bovine serum albumin as standard.
Western blot analysis of cell lysates
Western blot analysis of biopsy specimens from subjects with
UC was performed for TJ-proteins Claudin-1,-2,-4,-7, and their
expression was quantified by densitometry.
Total cell lysates from intestinal biopsies were prepared.
After protein measurement, aliquots of cell lysates containing
equal amounts of protein were mixed with 4 Laemmli’s
reducing sample buffer, boiled at 95 C for 5min and loaded
onto 12% polyacrylamide-bis-acrylamide gels. Following SDS-
PAGE, proteins were transferred to pure PVDF membranes
(Bio-Rad Laboratories), as reported by Laemmli.[20] After
transfer, the membranes were washed with phosphate-buf-
fered saline containing 0.1% Tween 20 (pH 7.4) (TPBS) at
room temperature, incubated overnight at 4 C with the spe-
cific primary antibody (Claudin-1, -2, -4, -7), washed again,
and then incubated for 60min with the relative secondary
antibody. The membranes, after three washes with TPBS,
were treated with the chemiluminescent substrate and
enhancer (ECL or ECL plus, Amersham). Blots were analyzed
by Chemi-Doc (Bio-Rad) utilizing the Quantity One program
(Bio-Rad). Protein bands were normalized using the respective
b-actin protein band. Densitometric data are given relative to
vehicle, set equal to 100. Western Blot Analysis was carried
out in duplicate for each sample of culture.
IL-13 and IL-6 production measurement
At the end of 24 h culture period, supernatants were collected
and stored at -80 C until tested for IL-13 and IL-6. IL-13 and
IL-6 production was assayed in duplicate by ELISA using com-
mercial kits (Vinci-Biochem, Vinci, Italy) following the instruc-
tions from the manufacturer.
Statistical methods
Statistical significance was determined by either a one-way
ANOVA followed by a Bonferroni t-test or by a Student t-test.
Differences were considered significant at p< 0.05.
Ethical considerations
The study protocol was approved by the Medical Ethics
Committee, and with the Helsinki Declaration of 1975, as
revised in 1983. CE 2 maggio 2011, protocol 0016888, rif. 95/10.
Results
Levels of Claudin proteins and interleukins in intestinal
biopsies
The basal levels of Claudins (Cl-1, -2, -4, -7), IL-13 and IL-6
determined in biopsies obtained from non-inflamed and
inflamed tracts of colonic mucosa are reported in Table 2.
The data indicate that these levels are higher in the inflamed
tract in comparison with the non-inflamed one for Cl-1, CL-2,
IL-13 and IL-6. On the contrary, the levels of Cl-4 and Cl-7 are
higher in the non-inflamed than those detected in
inflamed tract.
Expression of TJ protein and effect of 1,25(OH)2D3 on
Claudin-1 and Claudin-2 protein levels in intestinal
biopsies of active UC subjects
The effects of 100 nM 1,25(OH)2D3 on claudin-1 and claudin-2
protein levels are depicted in Figures 1 and 2, respectively.
The comparison between protein levels of claudin-1 and clau-
din-2 determined in biopsies obtained from non-inflamed
and inflamed regions of colonic mucosa, and incubated with
vehicle alone, indicates that these levels are higher in the
Figure 1. Effect of 100 nM 1,25-dihydroxyvitamin D3 [D] on Claudin-1 protein
levels determined by Western blot analysis in biopsies obtained from ulcerative
colitis (UC) subjects after 24 h culture. The biopsies were taken from endoscopic
non-inflamed (NI) and inflamed (I) colonic mucosa. The densitometric values, nor-
malized with the use of the respective b-actin protein band, are reported as the
percentage of the control value (cells treated with vehicle alone). Each densito-
metric value represents the mean± S.D. of 10 separate experiments. *p< 0.05 (in
comparison with vehicle).
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 3
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ita
 D
eg
li S
tud
i d
i F
ire
nz
e],
 [M
ari
a S
tio
] a
t 0
3:1
0 2
6 M
ay
 20
16
 
inflamed region in comparison with the non-inflamed one,
with an increase of about 270 and 288%, respectively (as
reported in Table 2). The treatment with 1,25(OH)2D3 induces
a significant decrease of claudin-1 and claudin-2 in both non-
inflamed and inflamed intestinal region.
Expression of TJ protein and effect of 1,25(OH)2D3 on
claudin-4 and claudin-7 protein levels in intestinal
biopsies of active UC subjects
The effects of 100 nM1,25(OH)2D3 on claudin-4 and claudin-7
protein levels are depicted in Figures 3 and 4, respectively.
Differently from what observed for claudin-1 and claudin-2,
claudin-4 and claudin-7 protein levels, remarkably decrease in
the inflamed region in comparison with the non-inflamed one,
and this decrease is of about 50 and 70%, respectively (as
reported in Table 2). When the biopsies were incubated with
1,25(OH)2D3, a notable increase is observed in both non-
inflamed and inflamed intestinal region. This increase is of
about 370 and 470% in non-inflamed and inflamed intestinal
region for claudin-4 and of about 250 and 240% for claudin-7.
Effect of 1,25(OH)2D3 on IL-13 and IL-6 levels in
intestinal biopsies of active UC subjects
The effects of 100 nM 1,25(OH)2D3 on IL-13 and IL-6 levels
in intestinal biopsies of active UC are depicted in Figures 5
and 6, respectively. IL-13 levels, determined in culture
medium of biopsies obtained from non-inflamed and
inflamed regions of colonic mucosa and incubated with
vehicle alone, are noteworthy increased in the inflamed
region in comparison with the non-inflamed one of about
247% (Table 2). When the biopsies were incubated with
1,25(OH)2D3, a remarkable decrease is observed in inflamed
intestinal region, where the decrement is of about 50%. On
the contrary, a slight and non-significant decrease is
observed in non-inflamed intestinal region.
IL-6 levels, determined in the same experimental condi-
tions, are remarkably increased in the inflamed region in
comparison with the non-inflamed one of about 280% (Table
2). The incubation with 1,25(OH)2D3 induces a significant
decrease of IL-6 levels in both non-inflamed and inflamed
intestinal region. This decrease is of about 28%.
Figure 2. Effect of 100 nM 1,25-dihydroxyvitamin D3 [D] on Claudin-2 protein
levels determined by Western blot analysis in biopsies obtained from ulcerative
colitis (UC) subjects after 24 h culture. The biopsies were taken from endoscopic
non-inflamed (NI) and inflamed (I) colonic mucosa. The densitometric values, nor-
malized with the use of the respective b-actin protein band, are reported as the
percentage of the control value (cells treated with vehicle alone). Each densito-
metric value represents the mean ± S.D. of 10 separate experiments. *p< 0.05 (in
comparison with vehicle).
Figure 3. Effect of 100 nM 1,25-dihydroxyvitamin D3 [D] on Claudin-4 protein
levels determined by Western blot analysis in biopsies obtained from ulcerative
colitis (UC) subjects after 24 h culture. The biopsies were taken from endoscopic
non-inflamed (NI) and inflamed (I) colonic mucosa. The densitometric values, nor-
malized with the use of the respective b-actin protein band, are reported as the
percentage of the control value (cells treated with vehicle alone). Each densito-
metric value represents the mean ± S.D. of 10 separate experiments. *p< 0.05 (in
comparison with vehicle).
Figure 4. Effect of 100 nM 1,25-dihydroxyvitamin D3 [D] on Claudin-7 protein
levels determined by Western blot analysis in biopsies obtained from ulcerative
colitis (UC) subjects after 24 h culture. The biopsies were taken from endoscopic
non-inflamed (NI) and inflamed (I) colonic mucosa. The densitometric values, nor-
malized with the use of the respective b-actin protein band, are reported as the
percentage of the control value (cells treated with vehicle alone). Each densito-
metric value represents the mean± S.D. of 10 separate experiments. *p< 0.05 (in
comparison with vehicle).
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Discussion
Inflammatory bowel disease causes a strong increase in the
expression of claudin-2, while normal colons have low levels
of claudin-2.[8,21]
In the present study, we determined the levels of claudins
and of two cytokines, IL-13 and IL-6, in active UC.
The increase of claudin-1 in the inflamed-tract of colon, in
our study, is in contrast to that reported by Oshima et al., [5]
who found that claudin-1 levels were unchanged in active UC
compared to controls. The disagreement with our data could
be explained by different biopsy sampling or disease activity
at the level of biopsies. Their biopsy specimens were
obtained endoscopically from the rectum, while in our studies
the biopsies were obtained from truly inflamed and non-
inflamed mucosa, mainly descending or sigmoid colon. In
accordance with our data, Oshima et al. [5] show that the
expression of claudin-2 was significantly elevated and the
expression of claudin-4 and claudin-7 was markedly
decreased in active UC. Claudin-2 has been shown to induce
cation-selective channels in the TJ of tight epithelial cells,
resulting in an increased paracellular permeability.[22] In IBD,
claudin-1 and claudin-2 expression correlated positively with
inflammatory activity.[23] Our study that reports a dramatic
increase of claudin-2 in subjects with active UC, related to the
impaired barrier function in active UC, provides strong evi-
dence for the protective role of 1,25(OH)2D3 on barrier
function.
In accordance with Prasad et al.,[21] our study indicates
claudin-2 levels are elevated in inflamed colonic biopsies. On
the contrary, claudin-4 and claudin-7 were present through-
out NI and were reduced in the I mucosa. The exposure for 3
days to IL-13 leads to a marked increase in claudin-2 expres-
sion, while no changes for claudin 3 or 4 were observed.[21]
IL-13 is a key effector cytockine in UC stimulating apoptosis
and up-regulation of claudin-2 expression.[7] This effect of IL-
13 on claudin-2 expression is in accordance with our results,
where IL-13 levels in colonic biopsies of active UC subjects
were determined. Our results indicate a marked increase of
these levels in the inflamed-tract compared to the non-
inflamed one (about 247%), and a decrease of IL-13 levels
(about 50%) when the biopsies obtained from the inflamed
tract were incubated for 24 h with 1,25(OH)2D3. The elevated
levels of IL-13 could be responsible of claudin-2 increase. We
demonstrated that vitamin D treatment is able to reduce the
levels of IL-13 and claudin-2. It is possible that the effect on
claudin-2 exerted by vitamin D is a consequence of the
inhibitory action exerted by vitamin D on IL-13. In fact, vita-
min D by reducing IL-13 levels, could be able to report clau-
din-2 to normal levels.
IL-13 is a potential therapeutic target for controlling muco-
sal inflammation in UC and it is plausible that vitamin D,
could be an effective strategy to treat UC, by regulating IL-13
production.
Considering our results, we suggest that IL-13 is one of
the mechanistic drivers of altered claudin-2 expression in UC.
However, the current literature on levels of IL-13 in IBD is
conflicting with studies, which report either increased [24] or
decreased levels.[25,26] In a recent study, Biancheri et al. [27]
have measured the IL-13 production by mucosal explants and
activated lamina propria mononuclear cells and did not
observe any difference among CD, UC, and control subjects.
IL-13, considered as an effector cytokine in UC, is not dif-
ferentially secreted between inflamed and non-inflamed areas
of gut of UC subjects and in most cases it is below detection
limit.[28] The role of IL-13, as Th2 effector and its correlation
with claudin-2 needs further investigations. IL-6 is the pre-
dominant cytokine found in culture supernatant of inflamed
areas of UC subjects and its concentration correlates with the
Mayo endoscopic score.[28] We found increased levels of IL-6
in inflamed areas of UC subjects, in accordance with Bernardo
et al.,[28] and observed that Vitamin D decreased these levels
both in inflamed and non-inflamed areas of colonic biopsies.
Our results indicate that, contrary to that observed for
claudin-1 and claudin-2, the expression of claudin-4 and clau-
din-7 markedly decreases in inflamed tract with respect to
non-inflamed tract of active UC subjects. Our data are in
accordance with Oshima et al.[5] In our study, when the biop-
sies were incubated for 24 h with 1,25(OH)2D3, a notable
increase of claudin-4 and claudin-7 levels were registered
both in inflamed and non-inflamed-tract. Claudins may func-
tion not only as sealing molecules in TJ, but also exert
Figure 5. Effect of 100 nM 1,25-dihydroxyvitamin D3 [D] on IL-13 levels, deter-
mined by ELISA kit in culture medium, incubating the biopsies obtained from
ulcerative colitis (UC) subjects after 24 h culture. The biopsies were taken from
endoscopic non-inflamed (NI) and inflamed (I) colonic mucosa. The values are
reported as the percentage of the control value (cells treated with vehicle alone).
In NI tract, 34.4 ± 3.2 and in I tract 85.1 ± 8.1 pg IL-13/mg of protein were pre-
sent. Each value represents the mean ± S.D. of 10 separate experiments.
*p< 0.01 (in comparison with vehicle).
Figure 6. Effect of 100 nM 1,25-dihydroxyvitamin D3 [D] on IL-6 levels, deter-
mined by ELISA kit in culture medium, incubating the biopsies obtained from
ulcerative colitis (UC) subjects after 24 h culture. The biopsies were taken from
endoscopic non-inflamed (NI) and inflamed (I) colonic mucosa. The values are
reported as the percentage of the control value (cells treated with vehicle alone).
In NI tract, 104.8 ± 11.3 and in I tract 289.5 ± 29.4 pg IL-6/mg of protein were pre-
sent. Each value represents the mean ± S.D. of 10 separate experiments.
*p< 0.05 (in comparison with vehicle).
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regulatory function.[29] Our findings suggest that claudins
play an important biological role in the maintenance of the
intestinal barrier function and that altered levels of TJ-protein,
particularly the down-regulation of claudin-4 and claudin-7,
and the up-regulation of claudin-2 are involved in the
impaired barrier function in active UC. We have shown that
vitamin D could exert a crucial regulatory role on barrier func-
tion down-regulating claudin-2 and redistributing claudin-4
and claudin-7.
In IBD, an alteration of the expression and distribution of TJ
is present. Moreover, TJ proteins are involved in the neoplastic
transformation to which IBD patients are subjected. Although
the relationship between claudin modifications and IBD-associ-
ated neoplasia has not been deeply examined, it is well estab-
lished that patients with IBD are at an increased risk of
developing colorectal carcinoma. In particular, emerging data
suggest that the risk of cancer in IBD may be related to the
severity of inflammation,[30] suggesting that chronic injury
may accelerate or otherwise contribute to neoplastic trans-
formation. Increased claudin-1 and claudin-2 expression may
be involved at early stages of transformation in IBD-associated
neoplasia, indicating a potential association between claudin-1
and claudin-2 expression and elevated neoplastic risk.[23] In
addition, a reduction (2.7-fold) in the claudin-7 mRNA level in
biopsies from individuals with carcinoma was reported.[31] A
reduction in claudin-7 mRNA was also detected in mild/moder-
ate dysplasia, severe dysplasia, and carcinoma compared to a
control sample from the same individual.
In our opinion, the results of our study are of particular
interest, as they indicate that vitamin D plays an important
regulatory role on TJ proteins and, consequently, on the
integrity and functionality of the intestinal barrier. In fact, we
have demonstrated that vitamin D is able to decrease clau-
din-2 and claudin-1 levels and to up-regulate claudin-4 and
claudin-7, which are decreased in UC. Vitamin D may there-
fore be suggested as a possible therapeutic agent in IBD, tak-
ing also into account that an association between vitamin D
deficiency and IBD risk was found.[11,32]
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